0001209191-20-002595.txt : 20200108
0001209191-20-002595.hdr.sgml : 20200108
20200108180143
ACCESSION NUMBER: 0001209191-20-002595
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200107
FILED AS OF DATE: 20200108
DATE AS OF CHANGE: 20200108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brege Laura
CENTRAL INDEX KEY: 0001365619
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 20516649
MAIL ADDRESS:
STREET 1: C/O ONYX PHARMACEUTICALS, INC.
STREET 2: 2100 POWELL STREET
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-07
0
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001365619
Brege Laura
C/O ACADIA PHARMACEUTICALS INC.
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO
CA
92130
1
0
0
0
Common Stock
2020-01-07
4
M
0
10000
1.75
A
10000
D
Common Stock
2020-01-07
4
S
0
10000
42.19
D
0
D
Stock Option (Right to Buy)
1.75
2020-01-07
4
M
0
10000
0.00
D
2021-06-09
Common Stock
10000
0
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The option is fully vested and exercisable.
/s/ Austin D. Kim, Attorney-in-Fact
2020-01-08